Clinical Outcomes of Patients Treated for Candida auris Infections in a Multisite Health System, Illinois, USA

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Arensman, Kellie ; Miller, Jessica L. ; Chiang, Anthony ; Mai, Nathan ; Levato, Joseph ; LaChance, Erik ; Anderson, Morgan ; Beganovic, Maya ; Dela Pena, Jennifer
• Description:
  Candida auris is an emerging fungal pathogen that is typically resistant to fluconazole and is known to cause healthcare-associated outbreaks. We retrospectively reviewed 28 patients who had >1 positive culture for C. auris within a multisite health system in Illinois, USA, during May 2018-April 2019. Twelve of these patients were treated as inpatients for C. auris infections; 10 (83%) met criteria for clinical success, defined as absence of all-cause mortality, C. auris recurrence, and infection-related readmission at 30 days from the first positive culture. The other 2 patients (17%) died within 30 days. Most patients (92%) were empirically treated with micafungin. Four (14%) of 28 total isolates were resistant to fluconazole, 1 (3.6%) was resistant to amphotericin B, and 1 (3.6%) was resistant to echinocandins. Our findings describe low rates of antifungal resistance and favorable clinical outcomes for most C. auris patients.
• Subjects:
  Antifungal Agents Candidiasis, Invasive Humans Microbial Sensitivity Tests Retrospective Studies
• Source:
  Emerg Infect Dis. 26(5):876-880
• Pubmed ID:
  32310077
• Pubmed Central ID:
  PMC7181927
• Document Type:
  Journal Article
• Place as Subject:
  Illinois
• Location:
  North America
• Volume:
  26
• Issue:
  5
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:da56f2954a313716fc15c38572ebefc46df1fcb568a2ccee0bd3c1afeb6b748c
• Download URL:
  https://stacks.cdc.gov/view/cdc/87677/cdc_87677_DS1.pdf
• File Type:
  [PDF - 1.58 MB ]